Broward Health Medical Center

Summary

Broward Health Medical Center is a medical facility located in Fort Lauderdale, Florida. This center is recognized for care of Breast Cancer, Cancer, Leukemia, Lymphoma, Neuroblastoma and other specialties. Broward Health Medical Center is involved with conducting 244 clinical trials across 402 conditions. There are 8 research doctors associated with this hospital, such as Hector M. Rodriguez-Cortes, Brian Slomovitz, Shannon B. Keating, and Mehmet F. Hepgur.

Top PIs

Clinical Trials running at Broward Health Medical Center

Ovarian Cancer

Breast Cancer

Breast cancer

Cancer

Cervical Cancer

Lung Cancer

Uterine Cancer

Prostate Cancer

Fallopian Tube Cancer

Testicular cancer

LY4170156

for Ovarian Cancer

This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if Sofetabart Mipitecan works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.

Recruiting

2 awards

Phase 3

4 criteria

Trastuzumab Deruxtecan + Bevacizumab

for Ovarian Cancer

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Recruiting

2 awards

Phase 3

5 criteria

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria